Search results for " Immunotherapy"

showing 10 items of 272 documents

Chaperonopathies and chaperonotherapy. Hsp60 as therapeutic target in cancer: potential benefits and risks.

2013

In this minireview we focus on Hsp60 as a target for anticancer therapy. We discuss the new concepts of chaperonopathies and chaperonotherapy and present information on Hsp60 localization in the cell membrane of human tumor cells. We describe novel mechanisms for Hsp60 reaching the extracellular environment that involve membrane-associated stages, as well as data on anti-Hsp60 antibodies found in human sera, both in normal subjects and patients affected by autoimmune diseases. Finally, we discuss possible therapeutic applications of anti-Hsp60 antibodies in cancer treatment, evaluating also side effects on non-tumor cells. In conclusion, the way for investigating Hsp60-targeted anti-tumor t…

animal structuresCellchemical and pharmacologic phenomenaAntineoplastic AgentsBiologycomplex mixturesRisk AssessmentCell membraneDrug Delivery SystemsRisk FactorsNeoplasmsDrug DiscoverymedicineExtracellularAnimalsHumansSecretionPharmacologyMechanism (biology)fungiCancerChaperonin 60medicine.diseasemedicine.anatomical_structureImmunologybiology.proteinCancer researchHsp60 Cpn60 HSPD1 plasma membrane antibodies autoantibodies antitumor immunotherapy anticancer therapy chaperonopathies human sera.HSP60AntibodyCurrent pharmaceutical design
researchProduct

Achieving dendritic cell subset-specific targeting in vivo by site-directed conjugation of targeting antibodies to nanocarriers

2021

AbstractThe major challenge of nanocarrier-based anti-cancer vaccination approaches is the targeted delivery of antigens and immunostimulatory agents to cells of interest, such as specific subtypes of dendritic cells (DCs), in order to induce robust antigen-specific anti-tumor responses. An undirected cell and body distribution of nanocarriers can lead to unwanted delivery to other immune cell types like macrophages reducing the vaccine efficacy. An often-used approach to overcome this issue is the surface functionalization of nanocarriers with targeting moieties, such as antibodies, mediating cell type-specific interaction. Numerous studies could successfully prove the targeting efficiency…

biologyChemistrymedicine.medical_treatmentCellFc receptorDendritic cellCell biologymedicine.anatomical_structureImmune systemAntigenCancer immunotherapybiology.proteinmedicineNanocarriersAntibody
researchProduct

Application of polymeric nanoparticles in immunotherapy.

2012

Purpose of review The purpose of the present review is to underline the importance of nanoparticulate carriers, such as polymeric nanoparticles, in the future development of safe and effective formulation in the field of immunotherapy against infectious diseases and cancer. Recent findings Polymeric nanoparticles can modulate the immune response, that is, by targeting antigens to dendritic cells that possess a crucial role in initiating immune responses, and might be potentially useful in immunotherapy. Summary In the last decades, significant progress in research and clinics has been made to offer possible innovative therapeutics for the management of infectious diseases and cancer. Polyme…

business.industrydendritic cellPolymersmedicine.medical_treatmentImmunologyCancerAdeptImmunotherapyPolymeric nanoparticlesmedicine.diseaseImmune systemantigenpolymeric nanoparticlesDrug Delivery SystemsCancer immunotherapyAntigenSettore CHIM/09 - Farmaceutico Tecnologico ApplicativomedicineCancer researchImmunology and AllergyAnimalsHumansNanoparticlesImmunotherapybusinessCurrent opinion in allergy and clinical immunology
researchProduct

Evolution of the Regulatory Landscape for Immunomodulatory Compounds and Personalized Therapeutic Cancer Vaccines

2014

The term cancer immunotherapy covers a huge range of different therapeutic interventions based on highly diverse medicinal products. Some immunotherapy products such as monoclonal antibodies have successfully been developed during the last years and contributed to major advances in cancer therapy. Development of cancer vaccines seemed to be more challenging. Nevertheless, some promising candidates are currently in late-stage clinical development, and one product (sipuleucel-T) was recently approved in the United States (USA) and in the European Union (EU). Additionally, cell therapy approaches based on adoptive lymphocyte transfer have recently come into focus due to surprisingly efficient …

business.industrymedicine.medical_treatmentCancer therapyCancerImmunotherapyBiologymedicine.diseaseBioinformaticsBiotechnologyCell therapySafety profileCancer immunotherapymedicinemedia_common.cataloged_instanceCancer vaccineEuropean unionbusinessmedia_common
researchProduct

Alfavīrusu vektoru izstrāde makrofāgu aktvācijai vēža imunoterapijā

2016

Audzēju-iefiltrējošiem makrofāgiem piemīt gan spēja veicināt audzēja attīstību, gan inhibēt, attiecībā no to aktivācijas stāvokļa. In vitro pētījumos ir ticis parādīts, ka, iedarbojoties ar interferonu-g (IFN-γ) kopā ar Toll-like receptora (TLR) ligandu, tika ierosināts M1 makrofāgu fenotips, kas tiek asociēts ar audzēja iznīcināšanu. Audzēja imūnterapiju varētu nodrošināt M1 makrofāgu fenotipa inducēšana audzēju-iefiltrējošos makrofāgos. Šajā darbā mēs izvērtējām Semliki meža vīrusa (SFV) vektoru potenciālu makrofāgu aktivācijā pret vēzi. SFV tika izmantots, lai konstruētu replikācijas defektīvus konstruktus ar ieklonētiem peļu audzēja nekrozes faktora (mTNFα), peļu IFNγ un cilvēka IFNγ gē…

cancer immunotherapyrecombinant SFVmacrophage activationinterferon-γBioloģijasurvival
researchProduct

Immunotherapy targeting colon cancer stem cells

2010

In the last 10 years, cancer stem cells have interested the scientific community because this small tumorigenic population is also associated with tumor progression in human patients and specific targeting of cancer stem cells could be a strategy to eradicate cancers currently resistant to conventional therapy. Clinical studies have recently demonstrated that adding immune therapy to chemotherapy has survival benefits in comparison with chemotherapy alone that can sensitize tumors to immune cell-mediated killing (e.g., increasing sensitivity of tumor cells to subsequent cytotoxicity by T cells via upregulation of death receptors DR5 and Fas). However, loss of MHC molecules is often observe…

cancer stem cellsAdoptive cell transferT-LymphocytesT cellImmunologyBiologyCell therapyNK-92T-Lymphocyte SubsetsCancer stem cellmedicinegamma delta T cellsHumansImmunology and AllergyNK cellSettore MED/04 - Patologia Generalecolon cancer stem cellschemoresistanceReceptors Antigen T-Cell gamma-deltaSuicide geneKiller Cells Naturalmedicine.anatomical_structureOncologyColonic NeoplasmsImmunologyCancer cellNeoplastic Stem CellsImmunotherapygamma delta T cells cancer stem cells chemoresistance immunotherapy NK cellStem cellImmunotherapy
researchProduct

Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia …

2020

The growing insights in the next-generation immunotherapy and the state-of-the-art advancement in targeted-agents significantly improved clinical outcome of cancer patients by pointing towards a unexplored Achilles' heel. Novel toxicity profiles have been uncovered, representing unmet medical needs. Thus, a panel of expert provide comprehensive pharmacological and clinical evidence, to provide a patient-tailored approach to metabolic adverse events associated with novel anti-cancer treatments. Prompted by the need of a multidisciplinary cooperation, a working group of Associazione Italiana Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD) and Societa Italiana Farmacologia (SIF)…

diabetes; dyslipidemia; hypercholesterolemia; hyperglycemia; hypertriglyceridemia; immunotherapy; metabolic effect; targeted therapy; Consensus; Humans; Immunologic Factors; Italy; Medical Oncology; Neoplasms; Physicians0301 basic medicinemedicine.medical_specialtyConsensusSettore MED/06 - Oncologia MedicaImmune checkpoint inhibitorsmedicine.medical_treatmentPatient riskhypertriglyceridemiaMedical OncologyTargeted therapy03 medical and health sciences0302 clinical medicineMultidisciplinary approachNeoplasmsPhysiciansmedicineHumansImmunologic FactorsIntensive care medicineAdverse effectdiabeteshypercholesterolemiabusiness.industrydyslipidemiametabolic effectHematologytargeted therapy030104 developmental biologyOncologyItalyClinical evidence030220 oncology & carcinogenesisMetabolic effectsPosition paperhyperglycemiaimmunotherapybusiness
researchProduct

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies

2015

We have developed a highly versatile platform for the systematic retrieval of T-cell receptors (TCRs) from single-antigen-reactive T cells and for characterization of their function and specificity. This approach enables rapid extraction of multiple TCRs from repertoires in individuals and not only broadens the diversity of TCRs suitable for clinical use, but also sets the stage for actively personalized immunotherapeutic strategies.

epitopeAdoptive cell transferImmunologyT-cell receptorhemic and immune systemschemical and pharmacologic phenomenaComputational biologyBiologypersonalized immunotherapybiological factorsEpitopeOncologyAntigen specificImmunologyImmunology and AllergyT cell engineeringT cell receptorAuthor's Viewtissuesadoptive cell transferOncoImmunology
researchProduct

Anti-inflammatory effects of pre-seasonal Th1-adjuvant vaccine to Parietaria judaica in asthmatics

2011

Nicola Scichilone, Chiara Minaldi, Roberta Santagata, Salvatore Battaglia, Gaetana Camarda, Vincenzo Bellia Dipartimento Biomedico di Medicina Interna e Specialistica (Di.Bi.M.I.S.), Sezione di Pneumologia, University of Palermo, Palermo, ItalyBackground: The ultra-short course pre-seasonal allergy vaccine, containing appropriate allergoids with the adjuvant monophosphoryl lipid A (MPL), may be effective in treating allergic symptoms. Objective: To explore the timing of the immunological responses to the pre-seasonal allergy vaccine.Methods: Four subcutaneous injections of the active product (Pollinex Quattro) were administered to 20 Parietaria-sensitive intermittent asthmatics (M/F: 12/8; …

exhaled breath condensatelcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentSettore MED/10 - Malattie Dell'Apparato Respiratoriomedicine.disease_causeAnti-inflammatoryAllergenJournal of Asthma and AllergymedicineImmunology and AllergyExhaled breath condensateOriginal ResearchAsthmabiologybusiness.industryasthmabiology.organism_classificationmedicine.diseaseinflammationpollenallergen asthma immunotherapy inflammation pollen exhaled breath condensateImmunologyParietaria judaicaimmunotherapylcsh:RC581-607businessAdjuvantallergenJournal of Asthma and Allergy
researchProduct

gammadelta T Cell Modulation in Anticancer Treatment

2010

The broad antimicrobial and antitumoral reactivity of Vgamma9Vdelta2 T cells, their ability to produce inflammatory cytokines involved in protective immunity against intracellular pathogens and tumors and their strong cytolytic and bactericidal activities suggest their direct involvement in immune control of cancers and infections. gammadelta T cells can be selectively activated by naturally occurring or synthetic phosphoantigens, and drugs that enhance their accumulation into stressed cells, offering new avenues for the development of gammadelta T cell-based immunotherapies. The recent development of small drugs selectively activating Vgamma9Vdelta2 T lymphocytes, which upregulate endogeno…

gamma delta T cells immunotherapy cancer
researchProduct